Abstract
New molecular entities (NMEs) causing time-dependent inhibition (TDI) of cytochrome P450 (CYP) enzymes are a concern because they can be responsible for drug–drug interactions (DDIs). DDIs occur when one drug affects the metabolism of a coadministered drug. This changes the exposure and clearance of a coadministered drug. The consequences are a risk of therapeutic efficacy of a drug to severe adverse drug reactions, leading to death. Thus, it is very important to identify any TDI early in the drug discovery process. In this chapter, potential DDIs for NMEs are evaluated by identifying time-dependent CYP inhibitors with human liver microsomes. The area under the curve (AUC) shift method is utilized by measuring the shift in AUC of the percent activity remaining versus the inhibitor concentration plot. By producing in vitro TDI data, clinical DDI can be understood and predicted. In vitro testing helps predict in vivo results, as well as helps in the design or avoidance of clinical trials.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Nagar S, Argikar UA, Tweedie DJ (2014) Enzyme kinetics in drug metabolism: fundamentals and applications. Humana, New York
Dahlinger D, Duechting S, Nuecken D, Sydow K, Fuhr U, Frechen S (2016) Development and validation of an in vitro, seven-in-one human cytochrome P450 assay for evaluation of both direct and time-dependent inhibition. J Pharmacol Toxicol Methods 77:66–75
Silverman RB (1995) Mechanism-based enzyme inactivators. Methods in enzymology enzyme kinetics and mechanism Part D: Developments in enzyme dynamics. Elsevier, Amsterdam, pp 240–283
Grimm SW, Einolf HJ, Hall SD, He K, Lim H, Ling KJ, Obach RS (2009) The conduct of in vitro studies to address time-dependent inhibition of drug-metabolizing enzymes: a perspective of the pharmaceutical research and manufacturers of America. Drug Metab Dispos 37(7):1355–1370
Khojasteh SC, Wong H, Hop CE (2011) Drug metabolism and pharmacokinetics quick guide. Springer, New York
Backman J (1999) Mibefradil but not isradipine substantially elevates the plasma concentrations of the CYP3A4 substrate triazolam*1. Clin Pharmacol Therap 66(4):401–407
Naritomi Y, Teramura Y, Terashita S, Kagayama A (2004) Utility of microtiter plate assays for human cytochrome P450 inhibition studies in drug discovery: application of simple method for detecting quasi-irreversible and irreversible inhibitors. Drug Metab Pharmacokinet 19(1):55–61
Mukadam S, Tay S, Tran D, Wang L, Delarosa EM, Khojasteh SC, Kenny JR (2012) Evaluation of time-dependent cytochrome P450 inhibition in a high-throughput, automated assay: introducing a novel area under the curve shift approach. Drug Metab Lett 6(1):43–53
Riley RJ, Grime K, Weaver R (2007) Time-dependent CYP inhibition. Expert Opin Drug Metab Toxicol 3(1):51–66
Dasgupta M, Tang W, Caldwell GW, Yan Z (2010) Use of stable isotope labeled probes to facilitate liquid chromatography/mass spectrometry based high-throughput screening of time-dependent CYP inhibitors. Rapid Commun Mass Spectrom 24(15):2177–2185
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Huang, J. (2021). Evaluation of Time-Dependent Cytochrome P450 Inhibition Using the Area Under the Curve Shift Method. In: Yan, Z., Caldwell, G.W. (eds) Cytochrome P450. Methods in Pharmacology and Toxicology. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-1542-3_7
Download citation
DOI: https://doi.org/10.1007/978-1-0716-1542-3_7
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-0716-1541-6
Online ISBN: 978-1-0716-1542-3
eBook Packages: Springer Protocols